Latest Videos

Prof Harrington talks to ecancertv at ASCO 2014 about a randomised phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) for...
Prof Sznol at ASCO 2014 about concurrent treatment with immunotherapy drugs ipilimumab and nivolumab produces an unprecedented median survival of roughly three and a half years (40 months) for patient...
Dr Hoos talks about his investigation of immunological and targeted approaches being combined in particular ways to successfully treat metastatic melanoma with the aim to expand the approach to other...
R. Dummer explains how deeper understanding of molecular biology is relevant for treatment decision in patients with diverse group of melanomas, progress in research of biomarkers.
J. Larkin describes key molecular pathways in melanoma, focussing on RAS-RAF-MEK-ERK. He describes NRAS-driven and other molecularly defined subgroups, MEK as a therapeutic target, data with MEK inhib...
Richard W. Joseph, M.D., medical oncologist at Mayo Clinic in Florida talks about the most deadly form of skin cancer, known as melanoma. Here he explains the differences in the four stages of melanom...
Svetomir Markovic, M.D., Ph.D., explains how his research at the Mayo Clinic, which is focused on understanding opportunities to integrate different systemic treatment modalities into more-effective t...
Dr James Chim, Professor and Head of Dept of Myeloma at University of Hong Kong gave a presentation on the approaches to relapsed / refractory Multiple Myeloma at BTG2013, Hong Kong
Dr. Sara Hurvitz and Dr. Antoni Ribas of UCLA preview the new melanoma therapies to be presented at the 2012 ASCO meeting